Skip to main content
. 2025 Sep 18;16:1617602. doi: 10.3389/fpsyt.2025.1617602

Table 2.

Reporting of characteristics advised against in the guidelines before, during, and after legislation changes legalizing AS.

Coding categories Total n (all 3 periods) (n = 906) Period 1 (2017–2019) (n = 103) Period 2 (2020–2021) (n = 719) Period 3 (2022) (n = 84) Comparison of period 1 vs. 21 Comparison of period 2 vs. 31
Characteristics advised against in the guidelines
Step-by-step description of AS 113 (12.5) 6 (5.8) 74 (10.3) 33 (39.3) 2.05 54.74***
Monocausality 129 (14.2) 40 (38.8) 70 (9.7) 19 (22.6) 65.82*** 12.67***
Celebrity 39 (4.3) 13 (12.6) 13 (1.8) 13 (15.5) n/a*** n/a***
Substance name 37 (4.1) 5 (4.9) 22 (3.1) 10 (11.9) n/a n/a***
Romanticization/glorification 464 (51.2) 55 (53.4) 375 (52.2) 34 (40.5) 0.06 4.12*
Reference to the method of AS or suicide in the headline/sub-headline 20 (2.2) 6 (5.8) 12 (1.7) 2 (2.4) n/a* n/a
False myths 325 (35.9) 44 (42.7) 252 (35.0) 29 (34.5) 2.30 0.01
Stigmatizing language 304 (33.6) 27 (26.2) 268 (37.3) 9 (10.7) 4.79* 23.48***
Epidemic/wave/increase of AS 107 (11.8) 1 (1.0) 105 (14.6) 1 (1.2) 14.91*** 11.81***
Suggesting inevitability 188 (20.8) 19 (18.4) 158 (22.0) 11 (13.1) 0.66 3.57
Difficulty level to get AS approved or to carry out AS Yes, AS too difficult to carry out 158 (17.4) 29 (28.2) 102 (14.2) 27 (32.1) 13.12*** 17.99***
No clear valuation 736 (81.2) 72 (69.9) 607 (84.4) 57 (67.9) 13.22*** 14.42***
Yes, AS too easy to carry out 12 (1.3) 2 (1.9) 10 (1.4) 0 (0.0) n/a n/a
Help/contact for AS 195 (21.5) 30 (29.1) 138 (19.2) 27 (32.1) 5.47* 7.73**

Values are presented as frequencies with percentages given in parentheses. Symbols (*) indicate significant differences with chi-squared tests or, in case of low frequencies, Fisher’s exact tests; * p < 0.05, ** p < 0.01, *** p < 0.001 (two-tailed).

n/a = not applicable (Fisher’s exact test).

1The degrees of freedom are 1 for chi-squared tests.